日本老年起病类风湿关节炎患者生物制剂保留率的比较——ANSWER队列研究
这项多中心回顾性研究纳入2015至2022年日本登记队列中572例老年起病类风湿关节炎患者共835个治疗疗程,采用倾向评分比较JAK抑制剂与生物制剂DMARDs的药物保留率及停药原因。结果显示IL-6抑制剂保留率显著高于TNF抑制剂,JAK抑制剂和IL-6抑制剂因无效停药少于TNF抑制剂,但JAK抑制剂因不良事件停药高于TNF抑制剂。
要点
- IL-6抑制剂药物保留率显著高于TNF抑制剂(HR=0.38,95%CI:0.27,0.55,P<0.01)。
- JAK抑制剂因无效停药低于TNF抑制剂(HR=0.38,95%CI:0.22,0.66,P<0.01)。
- JAK抑制剂因不良事件停药高于TNF抑制剂(HR=2.86,95%CI:1.46,5.59,P<0.01)。
核心结论
- 在老年起病类风湿关节炎患者中,IL-6抑制剂和JAK抑制剂的药物保留时间长于TNF抑制剂,且因无效停药更少。
- 作者认为应以个体化视角看待JAK抑制剂的潜在风险。
研究设计与样本
- 多中心回顾性研究,纳入2015至2022年日本多中心观察性登记队列中的类风湿关节炎患者。
- 老年起病类风湿关节炎定义为发病年龄60岁及以上。
- 共纳入572例患者、835个治疗疗程:TNF抑制剂314个、IL-6抑制剂175个、CTLA4-Ig阻断剂228个、JAK抑制剂118个。
- 采用基于基线特征的倾向评分调整适应证混杂因素后比较药物保留率。
主要发现
- 调整基线特征后,IL-6抑制剂药物保留率显著高于TNF抑制剂(HR=0.38,95%CI:0.27,0.55,P<0.01)。
- 因无效停药:JAK抑制剂低于TNF抑制剂(HR=0.38,95%CI:0.22,0.66,P<0.01),IL-6抑制剂低于TNF抑制剂(HR=0.29,95%CI:0.19,0.46,P<0.01),CTLA4-Ig阻断剂与TNF抑制剂HR相似。
- 调整后因不良事件停药发生率:JAK抑制剂高于TNF抑制剂(HR=2.86,95%CI:1.46,5.59,P<0.01)。
关键数值与推荐
- 老年起病类风湿关节炎定义:类风湿关节炎发病年龄60岁及以上。
- 因无效停药:JAK抑制剂HR=0.38(95%CI:0.22,0.66,P<0.01),IL-6抑制剂HR=0.29(95%CI:0.19,0.46,P<0.01),均以TNF抑制剂为参照。
- 因不良事件停药:JAK抑制剂HR=2.86(95%CI:1.46,5.59,P<0.01),以TNF抑制剂为参照。
- CTLA4-Ig阻断剂因无效停药的HR与TNF抑制剂相似。
临床怎么用
- 作者认为应以个体化视角看待JAK抑制剂的潜在风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This multicentre, retrospective study aimed to compare retention and reasons for discontinuation between Janus kinase inhibitors (JAKi) and biologic DMARDs in patients with elderly-onset rheumatoid arthritis (EORA). METHODS: Patients with RA enrolled in a Japanese multicentre observational registry between 2015 and 2022 were included. EORA was defined as RA with onset at age 60 or over. To adjust confounding factors by indication for initiation of TNF inhibitors (TNFi), IL-6 inhibitors (IL-6i), cytotoxic T-lymphocyte associated antigen 4 immunoglobulin (CTLA4-Ig) blockers, or JAKi, a propensity score based on baseline characteristics was used to compare drug retention. To assess the reasons for discontinuation, retention rates for ineffectiveness, adverse events and remission were analysed as secondary outcomes. RESULTS: A total of 572 patients with 835 treatment courses were identified (314 TNFi, 175 IL-6i, 228 CTLA4-Ig and 118 JAKi). After adjusting for differences in baseline characteristics, drug retention was significantly higher for IL-6i (hazard ratio [HR] = 0.38; 95% CI: 0.27, 0.55; P < 0.01) as compared with TNFi. Discontinuation due to lack of effectiveness was lower with JAKi (HR = 0.38; 95% CI: 0.22, 0.66; P < 0.01) and IL-6i (HR = 0.29; 95% CI: 0.19, 0.46; P < 0.01) as compared with TNFi although CTLA4-Ig had a similar HR to TNFi. The adjusted incidence of discontinuation due to adverse events was higher for JAKi (HR = 2.86; 95% CI: 1.46, 5.59; P < 0.01) than for TNFi. CONCLUSION: In EORA patients, IL-6i and JAKi had longer retention and less discontinuation due to ineffectiveness than TNFi. The potential risks of JAKi should be approached with an individualized perspective.
引用
- Jinno S, Onishi A, Hattori S, et al. Comparison of retention of biologics in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study. Rheumatology (Oxford). 2025. PMID: 38317442. doi:10.1093/rheumatology/keae081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。